Contemporary drug-eluting stents exhibit significant physical and pharmacological differences, though it remains unclear whether these variations meaningfully impact clinical outcomes in PCI patients.
Does the specific type of contemporary drug-eluting stent improve clinical outcomes in patients with significant coronary artery disease or acute coronary syndromes undergoing PCI?
Despite differences in physical and pharmacological properties among contemporary drug-eluting stents, it remains unclear if these differences meaningfully impact clinical outcomes, as most comparative trials are designed for non-inferiority.
Percutaneous coronary intervention (PCI) with implantation of a metallic drug-eluting stent (DES) is the mainstay of treatment in patients with significant coronary artery disease or acute coronary syndromes. DESs comprise a metallic platform and an anti-proliferative drug, usually released from a polymer coating. A wide range of DESs, differing in platform, polymer or drug, are currently available for clinical use. Although there are significant differences in the physical, biological and pharmacological properties of contemporary DESs, it remains unclear whether these impact meaningfully on clinical outcomes for patients undergoing PCI. Numerous randomised clinical trials have compared DESs in recent years, but these trials are typically designed to show non-inferiority, rather than superiority. Data from meta-analyses have helped to study this in larger populations, but have limitations. Improvement in stent design continues and ongoing work is exploring the effects of new innovations as well as gathering further data on existing devices. This review explores the development, properties and clinical efficacy of current-generation DESs, comparing different types where possible, whilst identifying areas of further work.
Parker et al. (Wed,) conducted a review in Coronary artery disease or acute coronary syndromes. Contemporary drug-eluting stents vs. Other drug-eluting stents was evaluated. Contemporary drug-eluting stents exhibit significant physical and pharmacological differences, though it remains unclear whether these variations meaningfully impact clinical outcomes in PCI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: